It has been demonstrated in a variety of cancers that parallel pathways, especially the PI3K/Akt signaling pathway, could promote tumor growth and result in adaptive resistance after inhibition of the MAPK signaling (39, 40). The gene discussed is AKT1; the disease is cancer.